Pharmacological assessment of drugs retained in the 1st and 24th WHO Essential Medicines List (1977–2025) Authors: Lilly Josephine Bindel, Roland Seifert Published: 2026 ABSTRACT AbstractThe Essential Medicines List (EML) provides international guidance for the selection of effective, safe, and essential drugs. Retained drugs were identified as medicines listed in both the 1st and 24th EML editions. The study aims to pharmacologically assess and to distinguish established therapeutic value from questionable or obsolete current relevance. Retained drugs were assessed by therapeutic value and indication-specific justification. Listed indications and the importance developments were compared between the 1st (1977) and 24th EML (2025). The justification of listing was assessed by guideline recommendations, efficacy and safety, scope of clinical usage, and availability of alternatives. A structured assessment algorithm was applied to assign drugs to therapeutic value categories. 129 retained drugs were assessed. Most EML indications did not change (n = 65), followed by specifications (n = 26), additions (n = 24), narrowing (n = 8), or change (n = 6). 71 drugs (55.0%) were classified as having constant importance, 20 (15.5%) as increasing, and 38 (29.5%) as declining. Drugs can be categorized in preserved and clearly justified value, niche value, requiring indication correction, and obsolescence. Nineteen drugs were identified where continued EML listing warrants discussion, mainly due to restricted or second-choice use, reduced efficacy, high pathogen resistance, and toxicity issues. Historical retention on the EML does not necessarily indicate unchanged therapeutic value. A structured pharmacological assessment can distinguish valuable from obsolete retained drugs. EML-listed drugs require regular reassessment to ensure that future EML editions remain clinically justified and relevant for public health.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00210-026-05555-8.Keywords: WHO, Essential Medicines List, Essential medicines, Rational pharmacotherapy, Risk–benefit, Guideline recommendation, Drug efficacy, Drug safety, Drug selection Introduction Every two years, the World Health Organization (WHO) publishes the “Model List of Essential Medicines”, which is also known as the “Essential Medicines List” (EML) (WHO 2025a). The first edition was introduced in 1977 (WHO 1977), while the most recent, the 24th edition of the EML was published in 2025 (WHO 2025b). Initially, the EML aimed to “extend the accessibility of the most necessary drugs to those populations whose basic health needs could not be met by the existing system,” with the “main objective […] to extend the primary health care coverage of the population” (WHO 1977). The first EML was primarily developed through expert opinion and consensus (WHO 1977). Current key criteria for the selection of essential medicines include evidence of efficacy and safety, public health need, cost-effectiveness, and availability in appropriate quality and dosing (WHO 2025a), with the introduction of cost-effectiveness as a criterion for the selection since 2002 (WHO 2002). Applications for changes to the EML are submitted by external stakeholders and assessed every two years by an independent WHO Expert Committee, which reviews the available evidence and formulates recommendations on additions, deletions, or modifications (WHO 2025b). Current EML revisions therefore follow a more formalized evidence-based application and review process compared with the primarily consensus-based development of the first EML. Over the years, the EML has developed into an important global guidance tool, serving as a reference for national EML development, drug supply priorities, choices for national health programs, and as an orientation for rational pharmacotherapy (Laing et al. 2003; Peacocke et al. 2022; WHO 2025a). Such guidance is particularly relevant in the context of substantial pharmacological innovation, expanding treatment options, and rising costs (Morgan et al. 2020; Ghinea 2024). However, the increasing number of available and often highly specialized therapies also raises the question which medicines should be considered truly essential, and whether the large list of essential medicines still fulfil their role as essential therapeutics. Historical retention alone does not necessarily imply unchanged therapeutic importance. Some drugs may have remained relevant for the same indication, whereas others may have gained new indications, shifted to another usage field, become restricted to reserve or second-choice use, or lost importance due to toxicity, resistance, declining availability, or replacement by more favourable alternatives. This is particularly relevant for anti-infective drugs, where changes in pathogen resistance patterns, evolving treatment guidelines, and shifting epidemiology can lead to more frequent changes in efficacy and recommended use. Retained drugs are defined as medicines listed in both the 1st (1977) and 24th (2025) EML edition and therefore retained for nearly five decades. Therefore, a reassessment of long-standing EML-listed drugs may provide further insight into how the concept of essential medicines has evolved over time and whether retained drugs still reflect current standards of rational and evidence-based pharmacotherapy. Such analysis may also help to identify drugs or indications requiring reconsideration, correction, or further discussion in future EML revisions. The present study focuses on a pharmacologically orientated assessment of the retained drugs. For this purpose, listed indications, guideline recommendations, evidence of efficacy and safety, scope of clinical usage, public health need, and availability of more favourable alternatives were evaluated. Three related but distinct levels of assessment were applied. First, the development of listed indications was assessed by comparing the EML 1977 with the EML 2025. Second, the trend in therapeutic importance was classified as constant, increasing, or declining. Third, the justification of continued EML listing was evaluated and integrated into therapeutic value categories, distinguishing drugs that remain clearly valuable from drugs with low value or obsolescence. The study contributes to the understanding of the long-term development of the EML. Thereby, future EML revisions are supported with regard to rational, evidence-based, and clinically justified essential pharmacotherapy. Methods Setting and data The 1st (1977) and 24th (2025) editions of the WHO Essential Medicines List (EML) were compared (WHO 2025b, 1977) to identify retained drugs. These are defined as drugs that were listed in both the 1st EML in 1977 and the 24th EML in 2025, thereby representing medicines with long-standing retention on the WHO EML. The analysis is based on WHO technical reports and corresponding EML lists, with particular focus on the listed indications in the 1st and 24th editions (WHO 2026). Literature sources for the assessment of retained drugs included current guidelines, reviews, drug information sources, and selected clinical literature addressing efficacy, safety, scope of clinical usage, and public health relevance. The sources were gathered through a primary literature search in PubMed and consultation of governmental and international health organization websites. If available, current guidelines or several publications with a high level of evidence were considered. The literature search and drug assessment were performed between the 20th November and the 8th December 2025 by L.J.B., while both authors reviewed and verified the summarized evidence and final drug assessments. Data extraction and classification were performed manually, and Excel was used for data organization. GraphPad Prism 11 and Microsoft Power Point were used for data visualization. In Fig. 1, a flowchart about the methodological procedure is provided, while Table 1 summarizes and explains the applied criteria for the drug assessment. The supplemental references correspond to the literature considered in the comprehensive assessment of the retained drugs presented in the supplemental material. These references were considered essential for an assessment that is as objective and verifiable as possible. Methodological flowchart and overview about considered aspects for the assessment of retained drugs Table 1Explanation of applied criteria and the characterisation of retained drugs in regard of the assessment of indication development, scope of clinical use, pharmacological assessment, and its justification of EML listing. For each overarching aspect, the included criteria and characterization options are provided, along with an explanationAspectCriterionCharacterizationExplanation Indication developmentunchanged indicationsame indication in EML 1977 and EML 2025specified indicationindication defined more precisely in EML 2025narrowed indicationrestriction to fewer or more specific indicationsadded indicationexpansion by additional indicationschanged indicationreplacement by substantially different indicationDevelopment of the scope in clinical useconstant usemaintained therapeutic relevance and established useincreasing usegrowing therapeutic importance or expanded usedeclining usereduced therapeutic importance or replacement by alternativesPharmacological assessmentRecommendation in guidelinesfirst-linepreferred standard treatmentsecond-linerecommended after failure or unsuitability of first-line therapyalternativeacceptable substitute treatmentreserverestricted use for selected or refractory casesnot recommendedno current recommendation in guidelinesEffectiveness and safetyeffectiveproven clinical efficacy with acceptable safetylimited efficacyreduced or insufficient therapeutic effectresistancereduced effectiveness due to microbial resistancetoxicityclinically relevant harmful effectsnarrow therapeutic indexsmall margin between effective and toxic doseadverse effectsclinically relevant tolerability or safety concernsPublic health needhigh disease burdenrelevance due to prevalence or mortalityprogram relevanceimportance in public health or control programsLMIC importancerelevance in low- and middle-income countriesavailabilityimportance due to accessibility or supplycost-effectivenesstherapeutic value in relation to costsJustification of EML listingretainedcontinued EML listing considered justifiedconsideration for deletioncontinued EML listing considered questionable Explanation of applied criteria and the characterisation of retained drugs in regard of the assessment of indication development, scope of clinical use, pharmacological assessment, and its justification of EML listing. For each overarching aspect, the included criteria and characterization options are provided, along with an explanation Assessment of retained drugs The listed indication in the 1st EML was compared with the listed indication in the 24th EML for each retained drug. Indications were extracted from explicit descriptions or deduced from the EML category in which the drug was listed. The development of indications was categorized as unchanged indication, specified indication, narrowed indication, added indication, or changed indication. Drugs were categorized as having constant, increasing, or declining scope in clinical use. Constant usage was assigned when a drug remained established for its listed indication. Increasing use was assigned when the drug gained relevance through broadened indications, pharmacological versatility, or increasing disease burden. Declining use was assigned when the drug showed restricted or second-choice use, reduced efficacy, resistance problems, relevant toxicity, declining availability, or replacement by more favourable alternatives. Declining use was not considered equivalent to obsolescence, because some drugs with declining importance may still have relevant niche, reserve, endemic, or low-resource use. Finally, the current therapeutic value and indication-specific justification of the EML-listing for each retained drug were assessed. Drugs were considered retained when the listing appeared justified. Drugs were considered for deletion when the current benefit–risk profile, guideline position, scope in clinical usage, or availability of more favourable alternatives made continued listing questionable. For some drugs, the listing itself was not considered obsolete, but specific indications were identified as requiring correction. Broader therapeutic value patterns were derived from the combined assessment of indication development, evidence of efficacy and safety, and development of importance. Results Development of listed indications of retained drugs Although all 129 retained drugs were listed in both the 1st and 24th editions of the EML, their indications were not necessarily unchanged. When comparing the EML 1977 with the EML 2025, the indication development could be categorized as unchanged, specified, narrowed, expanded, or changed to another indication or usage field (Table 2). A detailed overview of the indication development and all other assessed aspects for retained drugs is provided in Table S1. Table 2Overview about the absolute number of retained drugs and their relative distribution across the examined aspects. This includes changes in EML-listed indications, development of the scope in clinical use, and appropriateness of EML listing. In Fig. 2–4, a visualization of the statistics is providedAspectCharacterisationNumber of retained drugsShare of retained drugsEML-listed indicationno change6550.4%specification2620.2%narrowing86.2%change64.7%addition2418.6%Development of the scope in clinical useconstant7155.0%increasing2015.5%declining3829.5%Appropriateness of EML listingjustified11085.3%questionable1914.7% Overview about the absolute number of retained drugs and their relative distribution across the examined aspects. This includes changes in EML-listed indications, development of the scope in clinical use, and appropriateness of EML listing. In Fig. 2–4, a visualization of the statistics is provided The development of listed indications can be distinguished into unchanged indications, specified indications, narrowed indications, added indications, and changed indications or usage fields. Most retained drugs showed no relevant change in their listed indication between 1977 and 2025 (n = 65, 50.4%) (Fig. 2). Examples include folic acid for anaemia, rabies vaccine for immunization, ethambutol for tuberculosis, morphine for pain, oral rehydration salts for diarrhoea and rehydration, and potassium chloride for correction of electrolyte disturbances. Overview about the indications of retained drugs for which they are considered essential, in comparison of the 1st (1977) and 24th (2025) edition of the EML (corresponding to Table S1). Drugs are categorized whether their indication changed, changed not, was specified, narrowed, or whether indications were added. For each category, the number of retained drugs are provided A specification of the indication without a major change in the general usage field was observed for 26 drugs (20.2%). Examples include amitriptyline, which is now listed for depressive disorders, doxycycline, which is now assigned to defined infectious indications, and doxorubicin, which is now listed for several specified malignant diseases. Similar specifications were observed for several anti-infective and antineoplastic drugs, including cloxacillin, gentamicin, cyclophosphamide, fluorouracil, vincristine, and methotrexate. A narrowed or restricted indication (n = 8, 6.2%) was observed particularly among anti-infective drugs. Examples include ampicillin, now listed as a second-choice option for acute bacterial meningitis, chloramphenicol, now also restricted to a second-choice role for acute bacterial meningitis, procaine benzylpenicillin, now listed as a second-choice option for syphilis, and tetracycline, now listed for ophthalmological infections. Further examples of narrowed or specified use include amodiaquine, erythromycin, streptomycin, quinine, sulfadiazine, and pyrimethamine. Some drugs experienced a major change of indication (n = 6, 4.7%). Isosorbide dinitrate was initially listed for hypertension and is now listed for angina. For example, diazoxide was initially listed for hypertension and is now listed for hypoglycaemia, propranolol changed from hypertension to migraine prophylaxis, and ephedrine changed from asthma to use in local anaesthesia-related settings. The addition of indications was observed for 24 drugs (18.6%). Amphotericin B was initially listed for fungal infections and is now additionally listed for leishmaniasis. Epinephrine was initially listed for asthma and is now additionally listed for COPD, local anaesthesia, allergic reactions, arrhythmias, and mydriatic use. Acetylsalicylic acid gained additional indications in acute migraine attack, cardiovascular prevention, anticoagulant-related use, and juvenile joint disease. Further examples with added indications include methotrexate, dexamethasone, hydrocortisone, prednisolone, furosemide, spironolactone, calcium gluconate, potassium iodide, and salbutamol. Trends in the scope of clinical use of retained drugs The majority of drugs were classified as having a constant scope in clinical use in pharmacotherapy (n = 71, 55.0%) (Fig. 3, Table 2). This group includes drugs with continued relevance for their listed indications. Examples include activated charcoal for intoxication, benzathine benzylpenicillin for syphilis, doxycycline for several bacterial infections and malaria chemoprophylaxis, ethambutol for tuberculosis, cyclophosphamide and doxorubicin for cancer treatment, ferrous salt and folic acid for anaemia, lidocaine for arrhythmia and local anaesthesia, diazepam for anxiety disorders and seizures, morphine for pain, barium sulfate as radiocontrast medium, oral rehydration salts for diarrhoea, levothyroxine for thyroid hormone substitution, rabies vaccine for immunization, oxytocin as oxytocic, and glucose, sodium chloride, sodium lactate, and water for correction of water, electrolyte, and acid–base disturbances. Overview about the assessment of the scope in clinical use for the retained drugs within current years (corresponding to Table S1). Drugs are categorized by increasing, constant, or decreasing use. Notably, also drugs with a decreasing scope of clinical use can be considered appropriate for listing on the EML, since they may be essential in particular settings and indications A smaller group of 20 drugs (15.5%) was classified as having increasing usage, mostly due to added indications, broadened usage fields, or increasing clinical demand. Examples include benzylpenicillin, flucytosine, paromomycin, rifampicin, methotrexate, acetylsalicylic acid, allopurinol, naloxone, betamethasone, dexamethasone, hydrocortisone, levothyroxine, prednisolone, measles vaccine, typhoid vaccine, furosemide, spironolactone, calcium gluconate, epinephrine, and salbutamol. A further group was classified as having a declining scope of clinical use (n = 38, 29.5%). This group includes drugs with restricted indications, reduced preference, or a more limited current role compared with their original listing. Examples include amikacin, amphotericin B, sodium stibogluconate, sulfadiazine, sulfamethoxazole + trimethoprim, diazoxide, hydralazine, warfarin, amitriptyline, carbamazepine, phenobarbital, phenytoin, coal tar, tuberculin purified protein derivative, senna, ergometrine, mannitol, suxamethonium, and codeine. Identification of outdated and obsolete retained drugs Most identified retained drugs remain established in clinical practice, justified by current evidence, guideline recommendations, and scope in clinical usage. However, 19 drugs were identified where continued listing on the EML warrants discussion. These drugs include dimercaprol, amodiaquine, ampicillin, chloramphenicol, erythromycin, griseofulvin, melarsoprol, oxamniquine, procaine benzylpenicillin, quinine, streptomycin, tetracycline, dextran, digoxin, dopamine, glyceryl trinitrate, miconazole, pilocarpine, and neostigmine (Table 3 and S1). Table 3Summary of retained drugs which are considered with questionable therapeutic relevance, requiring discussion for deletion in the next EML. For each drug, its current EML 2025 indication is provided, as well as information about guideline recommendations, evidence of efficacy and safety, and public health need. More detailed information can be found in Table S1. Drugs are sorted alphabeticallyObsolete retained drugsIndication EML 2025Guideline recommendationEffectiveness and safetyPublic health needamodiaquinemalaria (curative, chemoprevention) in FDCcurative treatment of malaria, but not recommended for chemoprevention (MSF 2025c; Padberg 2015)effective, but toxicity and fatal adverse events are an issue, increasing resistance (Schlitzer 2010; AlKadi 2007; White 2014; Nyunt And Plowe 2009)not anymore recommended for long-term use, reserve malaria agent (Schlitzer 2010; Padberg 2015)ampicillinsecond choice for acute bacterial meningitisonly as an alternative for meningitis (Infectious Diseases Society of America 2025; Pfister et al. 2023)decreasing efficacy due to high bacterial resistance rates, acceptable safety (Kaushik et al. 2014; Heinz 2018; FDA 2023)not anymore recommended as first-choice, decreasing use (Infectious Diseases Society of America 2025; Pfister et al. 2023)chloramphenicolsecond choice for acute bacterial meningitisonly as reserve, not first choice for meningitis (EMC 2022; Moffa And Brook 2015; Sethi And Sethi 2025)effective, but toxicity issues (e.g. aplastic anaemia) (Moffa And Brook 2015; Sethi And Sethi 2025; BfR 2014)limited use (EMC 2022; Moffa And Brook 2015; Sethi And Sethi 2025)dextranplasma substitutealternatives often preferred depending on indication (crystalloids, albumin) (Miao And Guthmiller 2025)effective volume expander, but comparably risk of adverse events (anaphylaxis and coagulopathy), other crystalloids favoured for many indications (Isbister And Fisher 1980; Martin 2019; Rasmussen et al. 2015)declining, historical use, now rarely used and crystalloids are first-line (Martin 2019; Baglin 2012)digoxinarrhythmia, heart failurenot first-line, partly used as an adjunctive therapy for atrial fibrillation and symptomatic heart failure, availability of superior alternatives (Crane et al. 2024; Chen et al. 2015)evidence for symptomatic improvement but limited mortality benefit, narrow therapeutic index and arrhythmia risk require monitoring (Virgadamo et al. 2015; Jabri et al. 2022)marginal importance because availability of superior alternatives (Ziff And Kotecha 2016; Crane et al. 2024; Chen et al. 2015)dimercaprolintoxication (antidote)heavy metal intoxication (lead, arsenic, mercury) (Dawn And Whited 2023; Braitberg 2019)effective but significant toxicity (Long 2020; Dawn And Whited 2023; REMM 2025)declining usage because availability of more favourable alternatives like DMPS, problems with availability (Gerhardsson And Aaseth 2016; Whyte 2023)dopamineheart failurenot first-line in heart failure/acute treatment (Becerra et al. 2025; Bloom et al. 2023)moderately effective but preference of norepinephrine and dobutamine, use is associated with higher mortality (Becerra et al. 2025; Varriale 1999; Hosoya et al. 2025; Zhou et al. 2017)declining use, not recommended (Becerra et al. 2025)erythromycinophthalmologic infections (C. trachomatis, N. gonorrhoea)yes, but not effective in chlamydial infections, availability of alternatives (AAO 2025; Smith-Norowith et al. 2021; Duff 2015)yes in susceptible pathogens in ocular use but increasing bacterial resistance, acceptable safety, availability of alternatives (AAO 2025; NHS 2022a; Kim And Toma 2011; Cabrera-Aguas et al. 2024; Hsueh 2005)rarely used: already replaced in systemic therapy, availability of alternatives in ophthalmology (Hsueh 2005; Amsden 1996; Opthalmology Times 2009; Bremond-Gignac et al. 2011)glyceryl trinitrateanginashort-acting anti-anginal for acute chest pain, but preference of other alternatives (Arden 2011; Rousan And Thadani 2019; NICE 2016a)symptomatic improvement, but contraindicated for long-term use (tolerance development), risks of severe adverse events (Pearson And Butler 2021; Arden 2011; Wee et al. 2015; Münzel et al. 2005)declining use, alternatives like nitro-glycerine more favourable (NICE 2016a; Alyavi And Uzokov 2017)griseofulvinfungal infectionsonly in dermatophytes, replaced by other drugs in other indications (Aris et al. 2022; Bonifaz et al. 2024)effective but comparable (dermatophytes) and inferior (other fungal infections) to newer drugs (Bar et al. 2019; Möhrenschlager et al. 2002)declining use, not marketed anymore in many countries (DocCheck 2025; Bonifaz et al. 2024)melarsoproltrypanosomial infection (2nd stage African)reserve in trypanosomiasis (Lindner et al. 2025)decreasing effectiveness, high toxicity (Robays et al. 2008; Seixas et al. 2020)declining, replacement by alternatives (Lindner et al. 2025)miconazolefungal infections, topicalalternative for topical treatment of superficial fungal infections but not first-line (Mayser And Niehaus 2023; Bortolussi and Martin 2024)good efficacy but higher rate of adverse effects and drug interactions than available and favoured alternatives, available as OTC (GOV UK 2017; Gamil et al. 2024; Mijalijica et al. 2022; Watjer et al. 2023; Taudorf et al. 2019)high global prevalence of superficial mycoses (Ma et al. 2025; Havlickova et al. 2008)neostigminemyasthenia gravis, muscle relaxantalternative for reversal of neuromuscular blockade and myasthenia gravis, not first choice (Neely et al. 2025; Thilen et al. 2023)inferior to suxamethonium in anesthesia and pyridostigmine in mystenia gravis, less effective and more adverse effects (Urban et al. 2018; Fiorda Diaz et al. 2022; Mehndiratta et al. 2014; Neely et al. 2025)declining, but still used in some parts of the world (Urban et al. 2018)oxamniquineschistosomial infectionsreserve, mostly replaced by praziquantel (Danso-Appiah et al. 2022)effective in some settings, less broad spectrum than alternatives, increasing resistance (Alwan et al. 2023; Rugel et al. 2020; Chevalier et al. 2019)rarely used, praziquantel preferred (Sisay et al. 2025; Danso-Appiah et al. 2022)pilocarpinemiotic/glaucomahistoric alternative for acute angle-closure and chronic glaucoma, not recommended as first choice (Wagner et al. 2022)effective but high number of adverse effects, availability of more favourable alternatives, not recommended as first choice (NICE 2022a; Li et al. 2025; Ludwig And Seifert 2025)declining, replacement by newer drugs (Ludwig And Seifert 2025)procaine benzylpenicillinAccess group: second choice syphilisalternative but not first choice in syphilis (WHO 2016; CDC 2024b; MSHC 2021)increasing bacterial resistance, inferior to other second choice alternatives and need of frequent injections (CDC 2024b; Public Health Agency of Canada 2024; Greenwood And Irving 2012)rarely used, only if no other treatment is available (MSHC 2021)quininemalaria (curative)not recommended in WHO guidelines for malaria, listed as alternative in some national guidelines (Visser et al. 2022)substantial disadvantages in comparison to alternatives like artesunate (high toxicity, narrower therapeutic index, resistance issues and decreased efficacy, dosing) (Shanks 2016; Yeka et al. 2009; Cramer et al. 2011)use not recommended, inferior to alternatives (Yeka et al. 2009; SEAQUAMAT 2005)streptomycintuberculosissecond-line for tuberculosis, but preference of other reserve drugs (Ministry of Health And Family Welfare 2025; Cohen et al. 2020; Michalik et al. 2025)high resistance rates, toxicity issues (ototoxicity, nephrotoxicity), preference of newer alternatives as first line and amikacin as second line (Cohen et al. 2020; Rocha et al. 2021; Guo et al. 2025; Niemann 2023; Waters And Tadi 2023)reserve, declining use and withdrawal from guidelines (Cohen et al. 2020; Ministry of Health And Family Welfare 2025)tetracyclineophthalmologic infections (bacterial blepharitis, conjunctivitis, keratitis, trachoma)only recommended as use in eye drops in ophthalmology but not recommended in systemic therapy (MSF 2025e)effective in ophthalmologic conditions but availability of newer and favoured drugs, high bacterial resistance rates, unfavourable adverse effects in comparison with alternatives (Pearson et al. 2024; Xiong et al. 2024; Griffin et al. 2010; Bremond-Gignac et al. 2011)niche, declining use and importance, replaced by more favourable antibacterial drugs (Semenova et al. 2025; LaPlante et al. 2022) Summary of retained drugs which are considered with questionable therapeutic relevance, requiring discussion for deletion in the next EML. For each drug, its current EML 2025 indication is provided, as well as information about guideline recommendations, evidence of efficacy and safety, and public health need. More detailed information can be found in Table S1. Drugs are sorted alphabetically Several of the drugs considered for deletion belong to the anti-infective category. This includes amodiaquine, ampicillin, chloramphenicol, erythromycin, griseofulvin, melarsoprol, oxamniquine, procaine benzylpenicillin, quinine, streptomycin, and tetracycline. Other drugs considered for deletion are located in antidotes, blood components or plasma substitutes, cardiovascular treatment, dermatology, ophthalmology, and peripheral muscle relaxants. Among the drugs considered for deletion, several are listed only for narrow or second-choice indications in the EML 2025. Examples include ampicillin and chloramphenicol for acute bacterial meningitis, procaine benzylpenicillin for syphilis, streptomycin for tuberculosis, quinine for malaria, oxamniquine for schistosomiasis, melarsoprol for trypanosomiasis, pilocarpine for glaucoma, and neostigmine for myasthenia gravis or reversal of neuromuscular blockade (Infectious Diseases Society of America 2025; EMC 2022; MSHC 2021; Ministry of Health And Family Welfare 2025; Visser et al. 2022; Danso-Appiah et al. 2022; Lindner et al. 2025; Mayser And Niehaus 2023; Becerra et al. 2025; Crane et al. 2024; Wagner et al. 2022; Neely et al. 2025; Thilen et al. 2023). In contrast to drugs with a declining scope of clinical use but still justified niche use, these drugs showed additional concerns such as weak current guideline position, relevant toxicity, reduced efficacy, or the availability of more favourable alternatives. In addition to drugs considered for deletion, several drugs were identified where adjustment of specific listed indications may be required rather than deletion of the drug itself. This applies to metronidazole, sulfadiazine, hydrocortisone, and prednisolone. For these drugs, the assessment indicates that the drug remains relevant, while individual listed indications require reassessment. Discussion Interpretation of changes in listed indications of retained drugs The present assessment shows that retained drugs do not represent a uniform group of unchanged medicines in terms of their therapeutic context and scope of clinical use. Retention on the EML between 1977 and 2025 demonstrates historical continuity, but not necessarily unchanged pharmacological relevance. Some drugs remained listed for essentially the same indication, while others were retained because their indication was specified, narrowed, expanded, or shifted to a different therapeutic field (Table S1, Fig. 2). The specification of indications can partly be explained by the development of the EML itself. Earlier editions often used broader therapeutic categories, whereas later editions provide more precise categorizations. This is especially relevant for anti-infective and antineoplastic drugs, where rational pharmacotherapy requires exact assignment to pathogens, resistance patterns, tumour entities, or treatment regimens. For example, doxycycline is now assigned to defined infectious indications, while doxorubicin, cyclophosphamide, fluorouracil, vincristine, and methotrexate are linked to specified malignant diseases (Pearson et al. 2024; Holmes and Charles 2009; Kciuk et al. 2023; Gephart et al. 2025; Longley et al. 2003; Dhyani et al. 2022; Koźmiński et al. 2020). Therefore, specification does not necessarily indicate a change in importance, but rather a more precise description of current therapeutic use. Narrowed indications were observed particularly for anti-infective drugs. A narrowed listing often reflects that a drug is no longer suitable for broad use, but may still retain value in a specific indication. This is evident for several anti-infective drugs. For example, ampicillin and chloramphenicol are listed in the EML 2025 only as second-choice options for acute bacterial meningitis, while procaine benzylpenicillin is restricted to second-choice use in syphilis (Infectious Diseases Society of America 2025; Pfister et al. 2023; EMC 2022; Moffa And Brook 2015; WHO 2016; CDC 2024b; MSHC 2021). Similar narrowing was observed for tetracycline, erythromycin, quinine, streptomycin, sulfadiazine, and amodiaquine (NHS 2022a; Bremond-Gignac et al. 2011; Semenova et al. 2025; AAO 2025; Duff 2015; Visser et al. 2022; Cohen et al. 2020; RKI 2018; Dunay et al. 2018; Padberg 2015). For these drugs, the current EML listing no longer reflects broad therapeutic use, but a restricted or reserve indication. A change of usage field represents another important pattern. In these cases, continued listing is not primarily justified by the original indication, but by a newer therapeutic role. Diazoxide is now listed for hypoglycaemia, isosorbide dinitrate for angina, propranolol for migraine prophylaxis, and ephedrine for anaesthesia-related use (Chen et al. 2021; Newman-Lindsay et al. 2022; Rao et al. 2025; Qaseem et al. 2025; Versijpt et al. 2024; Kinsella et al. 2017). Conversely, drugs with added indications, such as epinephrine, salbutamol, spironolactone, furosemide, dexamethasone, hydrocortisone, and prednisolone, illustrate that older medicines may gain importance when their pharmacological mechanisms are useful across several clinical situations (Pashar et al. 2025; Wang And Lipner 2020; GINA 2025; GOLD 2025; Sinha et al. 2025; Resuscitation Council UK 2021; Heidenreich et al. 2022; Kitai et al. 2025; MSF 2025f; NHS 2025b; Pazderska And Pearce 2017; Kashyap And Chabri 2023; Walsh et al. 2025). Patterns in the change of scope in clinical usage The assessment of the scope in clinical use between the 1st and 24th EML allowed a differentiation of drugs in constant, increasing, and declining developments (Table 2 and S1, Fig. 3). This categorization is more informative than historical retention alone, because it separates drugs with stable therapeutic reliance from drugs with expanded demand and from drugs whose utilization has become limited. Drugs with constant scopes in clinical use usually address stable and fundamental therapeutic needs. Examples include activated charcoal for intoxication, lidocaine for arrhythmia and local anaesthesia, morphine for pain, oxytocin for obstetric use, oral rehydration salts for diarrhoea and rehydration, and potassium chloride, sodium chloride, sodium lactate, glucose, and water for correction of water, electrolyte, and acid–base disturbances (Zellner et al. 2019; Hartmann et al. 2025; Bahar And Yoon 2021; Güler et al. 2023; WHO 2018a; NICE 2016b; Kehl et al. 2021; Parry Smith et al. 2020; WHO 2006b; Munos et al. 2010; FDA 2014; Tinawi 2020; Miller et al. 2023; Ichai et al. 2014; Verma et al. 2024; EMA 2020). This is likely explainable through evidenced efficacy, acceptable safety, broad clinical applicability, and the absence of a need for more complex alternatives in many basic-care situations. Drugs with increasing scopes of clinical use often show either expanded indications or growing relevance due to disease burden and treatment standards. Methotrexate is now important not only in cancer treatment but also in rheumatologic and dermatologic conditions, acetylsalicylic acid gained relevance in cardiovascular prevention, naloxone gained importance as a life-saving antidote in MOR agonist overdose, and calcium gluconate has an important role in hypocalcaemia, hyperkalaemia, and calcium-channel inhibitor intoxication (Dattani 2025; DEA 2025); Friedman And Cronstein 2019; Perrotta et al. 2024; Koźmiński et al. 2020; Rao et al. 2025; Kumbhani et al. 2025; Hennessy et al. 2024; EMCDDA 2015; Chakraborty et al. 2024; St-Onge et al. 2017). The increasing importance of levothyroxine, salbutamol, furosemide, and spironolactone is also related to high or increasing prevalence of hypothyroidism, chronic airway diseases, and cardiovascular diseases (Kahaly And Gottwald-Hostalek 2022; Centanni et al. 2025; GINA 2025; GOLD 2025; Savarese et al. 2023; Wu et al. 2024). Consequently, increasing scope of clinical use often reflects a combination of pharmacological versatility and epidemiological relevance. Table 4 summarizes information about the retained drugs that are considered as experiencing increasing scopes in their clinical usage. Table 4Overview about retained drugs which are considered with increasing scopes in clinical usage. For each drug, its current EML 2025 indication is provided, as well as information about guideline recommendations, evidence of efficacy and safety, and public health need. More detailed information can be found in Table S1. Drugs are sorted alphabeticallyRetained drugsIndication EML 2025Guideline recommendationEffectiveness and safetyPublic health needacetylsalicylic acidpain, anti-inflammatory, acute migraine attack, anticoagulant, prevention of atherosclerotic CD, juvenile jointyes, first-choice for prevention of CV, anticoagulation, moderate pain and rheumatic disorders (Rao et al. 2025; Kumbhani et al. 2025; Ciurtin et al. 2025; Amaechi et al. 2021)strong evidence for analgesia and secondary prevention of CV, long-term adverse effects require risk–benefit assessment for primary prevention (Garcia And Aguiar 2025; Ciurtin et al. 2025; La Torre et al. 2025; Schachtel et al. 2010; Yilmaz et al. 2022)widely used for analgesia and CV prevention (Montinari et al. 2019; Garcia And Aguiar 2025)allopurinoltumour lysis syndrome, goutyes (NICE 2022b; Chan et al. 2025)evidence for gout prophylaxis and preventing hyperuricaemia in tumour lysis syndrome contexts, acceptable safety, hypersensitivity syndrome rare but serious (Cortes et al. 2010; Yang et al. 2015)widely used in gout and importance in oncology (Yang et al. 2015)benzylpenicillinfirst-choice severe community-acquired pneumonia, complicated severe acute malnutrition, sepsis in neonates and children, syphilisfirst line for susceptible streptococcal infections and neonatal sepsis (Fuchs et al. 2018; Marum et al. 2021; Bennett et al. 2012)efficacy and good safety, narrow-spectrum (Rote Liste 2025a; Marum et al. 2021)high need and widely used (Bennett et al. 2012; Bos et al. 2017)betamethasoneantiinflammatory, antipruritic, topicaltopical GCR agonist for inflammatory dermatoses (Wollenberg et al. 2025)strong efficacy for inflammatory skin diseases, local atrophy and systemic absorption risks with prolonged use, steroid-sparing strategies considered for long-term use (Wollenberg et al. 2025; Gisondi et al. 2024; Pofe et al. 2023)widely used in dermatology and rheumatology, importance in many short-term inflammatory conditions (Benzon et al. 2025)calcium gluconateantidote, nutritional supplementtreatment of hyperkalaemia and Ca-channel blocker toxicity, correction of hypocalcaemia, osteoporosis treatment (NOGG 2024; Chakraborty et al. 2024; Medicines And Healthcare products Regulatory Agency 2023; St-Onge et al. 2017)benefit in emergencies, effective in deficiencies, part of prevention regimes for osteoporosis in risk groups, mild adverse effects but risk of drug interactions (Shea et al. 2004; UKCPA 2025; Chakraborty et al. 2024; St-Onge et al. 2017)relevance in emergency and osteoporosis treatmentdexamethasoneallergic reaction, hormone replacement, cancer treatment (ALL, anaplastic large cell lymphoma, Burkitt lymphoma, multiple myeloma), emesiswidely recommended for multiple indications: as part of chemotherapy regimens, for severe allergic reactions, cerebral edema, and in specified severe respiratory inflammatory conditions (MSF 2025f; NHS 2025b)robust evidence across many indications including oncology adjuncts and life-saving in pediatric emergency, adverse effects significant but acceptable in indicated regimens (Giolito et al. 2025; Ottaiano et al. 2025; Mo et al. 2024; An et al. 2024; Weinstein et al. 2024)high need in oncology and emergency medicine (Ottaiano et al. 2025; Weinstein et al. 2024)epinephrineasthma, COPD, local anaesthetic, allergic reactions, arrhythmias, mydriaticfirst-line vasopressor in cardiogenic shock and anaphylaxis (Sinha et al. 2025; Resuscitation Council UK 2021; GINA 2025)effective in cardiogenic shock and symptom relief in acute respiratory obstruction, rapid onset, adverse effects acceptable (Bernstein et al. 2025; Lüsebrink et al. 2024; Numa et al. 2000)life-saving, widely used in emergency settingsflucytosinefungal infectionsyes (Sigera And Denning 2023; Harsanyi et al. 2017)effective but toxicity requires monitoring (Folk et al. 2016)importance in severe fungal infections (Harsanyi et al. 2017; Sprute et al. 2023)furosemidediuretics, heart failurefirst-line NKCC inhibitor in heart failure, symptomatic treatment in chronic kidney disease (KDIGO 2024; Kitai et al. 2025)effective in diuresis and reduction of fluid volume, symptom relief, mortality/morbidity benefit in heart failure, caution about adverse effects (e.g. hypovolemia, hypokalemia) and drug interactions (Song et al. 2025; Ho And Power 2010)widely used, globally high disease prevalence and need (Wu et al. 2024; Magdy et al. 2022)hydrocortisoneadrenal hormone substitution, anti-inflammatory (gastrointestinal, dermatology/topical), cancer treatment (ALL, Burkitt lymphoma), allergic reactionfirst-line replacement for adrenal insufficiency, cancer treatment and inflammatory conditions, but not recommended as standard in allergic shock (Pazderska And Pearce 2017; Whyte et al. 2022; Das a+nd Panda 2017; Ornetti et al. 2025)lifesaving adrenal replacement and effective in short-term anti-inflammatory effects, strong probability of chronic systemic adverse effects (Martinez And Sabatier 2025; Aldea et al. 2020; Das And Panda 2017; Ornetti et al. 2025; Yasir et al. 2023)essential in inflammatory conditions, endocrine disorders and part of cancer treatment regimens (Yasir et al. 2023)levothyroxinethyroid hormone substitutionhypothyroidism (Centanni et al. 2025)effective and safe when dosed and monitored appropriately, essential for brain development in children, need of individual dosage adjustment and control of TSH values (Centanni et al. 2025; Colucci et al. 2013; Esposito et al. 2022)essential in maintenance treatment of hypothyroidism, prevention of mental retardation in congenital hypothyroidism, high and expanding prevalence (Kahaly And Gottwald-Hostalek 2022; Seo et al. 2017)measles vaccinevaccinationroutine childhood immunization (WHO 2013)effective and safe, prevents high morbidity/mortality, mild and transient adverse effects (e.g. fever) possible (Dattani 2025; Benn And Aaby 2023; Dattani And Spooner 2025; Government of Canada 2025b)indispensable for global measles elimination goals (WHO 2013)methotrexatecytotoxic (ALL, acute promyelocytic leukaemia, anaplastic large cell lymphoma, Burkitt lymphoma, early stage breast cancer, gestational trophoblastic neoplasia, Langerhans cell histiocytosis, osteosarcoma), dermatology (not specified), anti-rheumatic (DMARDs), juvenile joint diseasesyes (Perrotta et al. 2024; Koźmiński et al. 2020)efficacy in cancer and rheumatology, but adverse effects and toxicity require monitoring (Perrotta et al. 2024; Koźmiński et al. 2020; Taylor et al. 2021; Hamed et al. 2022)widely used (Koźmiński et al. 2020; Friedman and Cronstein 2020)naloxoneantidoteantidote for MOR agonist overdose/induced respiratory depression (WHO 2025c)evidence for life-saving reversal of opioid overdose, rapid onset but short half-life, minimal adverse effects relative to benefit (Hennessy et al. 2024; EMCDDA 2015; Rzasa Lynn And Galinkin 2018)important in emergency care and public health/opioid use disorder (DEA 2025); Hennessy et al. 2024; EMCDDA 2015)paromomycinleishmaniac infectionsyes (Zhang et al. 2025)effective and acceptable safety (Kim et al. 2009; Salah et al. 2013; Matos et al. 2020)increasing importance in endemic areas (Zhang et al. 2025; Sundar And Chakravarty 2008)prednisoloneadrenal hormone substitution, anti-inflammatory (gastrointestinal, ophthalmology/topical), cancer treatment (ALL, anaplastic large cell lymphoma, Burkitt lymphoma, CLL, diffuse large B-cell lymphoma, follicular lymphoma, Hodkin lymphoma, Langerhans cell histiocytosis, metastatic castration-resistant prostate cancer, multiple myeloma), allergic reaction, seizues, cluster headachesystemic GCR agonist for many inflammatory, oncologic supportive and neurologic symptomatic uses, but not initial therapy in anaphylactic shock (Faggiano et al. 2022; Kashyap And Chabri 2023; Walsh et al. 2025)robust across many acute and chronic inflammatory and oncologic indications, in chronic use adverse effects expectable (Faggiano et al. 2022; Wijdicks 2024; Obermann And Holle 2020; Kashyap And Chabri 2023; Becker And Kaindl 2023; Offor et al. 2025)widely used across many medical fieldsrifampicinleprosy, tuberculosisyes (Sivakumaran et al. 2024; Haigh et al. 2024)effective and acceptable safety, use in combination therapies because of bacterial resistance risk (Sivakumaran et al. 2024; Richardus et al. 2021; Li et al. 2022; Kim et al. 2023a; Menzies et al. 2023)widely used globally (Haigh et al. 2024; Government of Canada 2025a, b)salbutamolasthma, COPDrescue bronchodilator for asthma and COPD (GINA 2025; GOLD 2025)short-acting beta-agonist for acute symptom relief, effective in short-term treatment but possible cardiovascular adverse effects and tolerance development in chronic use (GOLD 2025; GINA 2025; Ma et al. 2023; Haney And Hancox 2005; Marques And Vale 2022)high prevalence, widespread use and important treatment in acute situations, risk of overuse and worsening outcomes (Nwaru et al. 2020)spironolactonediuretics, heart failurefirst-line MRA for heart failure with reduced ejection fraction, treatment-refractory hypertension (Heidenreich et al. 2022; Carey et al. 2018)universal recommendation in heart failure, mortality reduction, but adverse effects (e.g. hypercalemia) require caution (Heidenreich et al. 2022; Chen et al. 2020; Prashar et al. 2025; Kosmas et al. 2018; Wang And Lipner 2020)widely used, high prevalence and burden of disease (Savarese et al. 2023; Kosmas et al. 2018)typhoid vaccinevaccinationprevention of typhus in endemic settings and high-risk travel (Brendan et al. 2015; WHO 2018c)safe and effective, reduction of morbidity and mortality (Gloeck et al. 2025; Batool et al. 2024)important in typhoid-endemic countries (Khan et al. 2017) Overview about retained drugs which are considered with increasing scopes in clinical usage. For each drug, its current EML 2025 indication is provided, as well as information about guideline recommendations, evidence of efficacy and safety, and public health need. More detailed information can be found in Table S1. Drugs are sorted alphabetically Drugs with declining scopes in clinical use form a heterogeneous group. However, they should not be interpreted as automatic obsolescence, because they may remain relevant in low-resource settings, or if first-choice alternatives are not available. This applies to phenobarbital, phenytoin, carbamazepine, warfarin, hydralazine, suxamethonium, and mannitol (Brodie And Kwan 2012; Bankole et al. 2024; Nevitt et al. 2019; ILAE 2020; Chin And Doogue 2025; Tran et al. 2025; NICE 2023; Mech And Seifert 2025; Ahmad et al. 2025; Kim et al. 2023b). In this context, it should also be acknowledged that changes in the scope of the clinical use or replacement by more favourable alternatives are not exclusively determined by intrinsic therapeutic value. Usage patterns may additionally be influenced by external factors such as pricing, availability, reimbursement policies, guideline adoption, and pharmaceutical marketing, which may affect prescribing behaviour independently of comparative efficacy or safety (Bindel and Seifert 2025a, 2025b). Reasons of obsolescence of initially essential retained drugs Several drugs were identified for which continued EML listing warrants discussion (Table 3 and S1). The most prominent group consists of older anti-infective drugs, because antimicrobial usefulness changes over time as resistance patterns, pathogen epidemiology, and preferred treatment regimens change. Reduced efficacy or resistance is central for ampicillin, erythromycin, tetracycline, streptomycin, quinine, and amodiaquine (Kaushik et al. 2014; Heinz 2018; Hsueh 2005; Bremond-Gignac et al. 2011; Cabrera-Aguas et al. 2024; Semenova et al. 2025; Cohen et al. 2020; Rocha et al. 2021; Guo et al. 2025; Shanks 2016; Yeka et al. 2009; SEAQUAMAT 2005; Visser et al. 2022). In these cases, the argument for deletion is based on a weaker benefit–risk and efficacy profile compared with available alternatives. Toxicity is another major reason. Dimercaprol is limited by significant toxicity and declining use due to the availability of less toxic alternatives, chloramphenicol is limited by rare but severe adverse effects such as aplastic anaemia, melarsoprol by high toxicity, and digoxin by limited mortality benefit, a narrow therapeutic index, and arrhythmia risk (Long 2020; Dawn And Whited 2023; Gerhardsson and Aesseth 2016; Mückter et al. 1997; Moffa and Brook 2015; Sethi And Sethi 2025; BfR 2014; Seixas et al. 2020; Lindner et al. 2025; Virgadamo et al. 2015; Jabri et al. 2022; Ziff And Kotecha 2016). A toxic drug can remain essential if it fills an unmet need, but it is considered inferior or obsolete when safer and similarly or more effective alternatives become available. A further pattern is inferiority compared with treatment alternatives. Dextran, dopamine, pilocarpine, and neostigmine remain pharmacologically effective, but are often less favourable than available alternatives in their respective indications (Martin 2019; Miao And Guthmiller 2025; Becerra et al. 2025; Bloom et al. 2023; Wagner et al. 2022; NICE 2022a; Urban et al. 2018; Hristovska et al. 2017; Jacob et al. 2025). Compromised availability also contributes to reduced relevance, as seen with griseofulvin and dimercaprol (DocCheck 2025; Bonifaz et al. 2024; Gerhardsson and Aesseth 2016; Whyte 2023). Furthermore, some drugs are not obsolete themselves, but specific listed indications require correction. Metronidazole remains important in anaerobic and protozoal infections, but its role in C. difficile infection has changed (NICE 2021; van Prehn et al. 2021; Hernández Ceruelos et al. 2019). Sulfadiazine remains relevant in toxoplasmosis but is not equally supported for all listed anti-infective indications (RKI 2018; Dunay et al. 2018). Hydrocortisone and prednisolone remain essential GCR agonists, but are not the initial life-saving treatment in anaphylactic shock, where epinephrine is considered as first-line (Whyte et al. 2022; Liyanage et al. 2017; Sinha et al. 2025; Resuscitation Council UK 2021). Categorization by therapeutic value Beyond the assessment of individual criteria, such as indications, development of the scope in clinical use and appropriateness of EML listing, broader patterns of current therapeutic value can be derived for retained drugs. These patterns allow a more transparent interpretation, resulting in a categorization in four groups: (A) unrestricted valuable, (B) valuable in niche use, (C) valuable for selected indications but requiring indication correction, and (D) low value and obsolete. Figure 4 visualizes the algorithm, while Table 5 summarizes characteristic patterns of the four categorizations. Overview of the assessment algorithm used to categorize retained drugs according to their therapeutic value for EML-listed indications (corresponding to Table 5). Drugs were first assessed regarding evidence of efficacy and safety for their listed indication. If evidence and safety were supported, the development of the scope of clinical use was considered and drugs were categorized as having appropriate listing with unrestricted value or appropriate listing with value in niche use. If evidence and safety were only partly supported, drugs were categorized as requiring correction of listed indications but retaining value in selected indications. If evidence and safety were not supported, drugs were categorized as obsolete and of low therapeutic value Table 5Typical patterns of therapeutic value observed among retained drugs. Summarized are characteristic patterns that were observed in the four assigned categories. Patterns are described according to changes in EML-listed indications, evidence of efficacy, benefit–risk profile, guideline recommendations, development of the scope in clinical use, and appropriateness of continued EML listing (corresponding to Table 2). Furthermore, a brief explanation and drugs are provided. A simplified algorithm for the assignment of therapeutic value categories can be found in Fig. 4CriterionA) Listing justified and clearly valuableB) Listing justified, but nicheC) Listing justified, but indication correction neededD) Listing not justified, obsoleteChange in EML-listed indicationsunchanged, specified, addedunchanged, specified, narrowedunspecificunspecificEvidence of efficacyrobust evidence for the listed indicationrobust evidence for use in selected settings and reserve situationsevidence for some indications; but weak or no evidence for other specific EML-listed indicationsweak evidence or reduced efficacy (loss of efficacy or inferior in comparison with alternatives)Benefit–risk profileacceptable safety profile, favourable benefit–risk ratioacceptable safety profile, benefit–risk ratio depending on indication and settingacceptable safety profile, favourable benefit–risk ratio for appropriate indicationsissues in safety profile, relevant toxicity, narrow therapeutic index, poor benefit–risk ratioGuideline recommendationfirst-line, standard treatment, broadly recommended optionreserve option, second-choice treatment, first-choice in specific settingsguideline support exists for selected uses, but not for the problematic listed indicationno longer recommended, rarely used, replaced by better alternatives, only historical useDevelopment of scope of clinical useconstant, increasingconstant, decliningunspecificdecliningAppropriateness of EML listingretainedretainedretained, but changes in listed indicationsdeletedInterpretationjustified EML listing, essential therapeutic rolejustified EML listing only with clearly defined indication or setting-specific justificationjustified EML listing, but correction/specification of listed indicationsquestionable EML listing, requires discussion for deletionExamples of retained drugsacetyl salicylic acid, epinephrine, measles vaccine, methotrexate, naloxone, spironolactonecoal tar, phenobarbital, diazoxide, ergometrine, hydralazine, phenytoinmetronidazole, sulfadiazine, hydrocortisone, tuberculin (PPD), suxamethoniumdextran, chloramphenicol, quinine, tetracycline, pilocarpine, neostigmine Typical patterns of therapeutic value observed among retained drugs. Summarized are characteristic patterns that were observed in the four assigned categories. Patterns are described according to changes in EML-listed indications, evidence of efficacy, benefit–risk profile, guideline recommendations, development of the scope in clinical use, and appropriateness of continued EML listing (corresponding to Table 2). Furthermore, a brief explanation and drugs are provided. A simplified algorithm for the assignment of therapeutic value categories can be found in Fig. 4 Retained drugs with broad and preserved therapeutic value (category A) are characterized by robust evidence of efficacy for their listed indications, an acceptable safety profile, established scope in clinical use, and a favourable benefit–risk ratio (magnitude of benefit). Acetylsalicylic acid illustrates this pattern. It has retained and expanded its relevance because it is used not only as an analgesic and antipyretic drug, but also in cardiovascular prevention, acute cardiovascular care, and selected rheumatic disorders (Rao et al. 2025; Kumbhani et al. 2025; Ciurtin et al. 2025; Amaechi et al. 2021). Its continued relevance is also reflected by a broad scope in clinical use in pain management and by its established role in the prevention of cardiovascular events (Montinari et al. 2019; Garcia And Aguiar 2025). Another example is epinephrine, which is essential in emergency situations such as anaphylaxis and resuscitation, but is also used in obstructive airway disease, local anaesthesia, and ophthalmological indications. Due to its rapid onset of effect and life-saving pharmacological actions, epinephrine remains a highly valuable drug in acute care and emergency pharmacotherapy (Bernstein et al. 2025; Lüsebrink et al. 2024; Numa et al. 2000). Drugs that remain valuable, but mainly in selected indications, reserve situations, or specific settings (category B) are usually characterised by declining general importance, but this does not make them automatically obsolete. Coal tar is an example. It is effective in psoriasis, but its use has declined in high-resource settings because of low convenience for patients, cosmetic disadvantages, and the availability of other effective alternatives such as calcipotriol (Chan 2025; Slutsky et al. 2010; Paghdal And Schwartz 2009; Elmets et al. 2021; Singh et al. 2013). Nevertheless, due to low costs, availability, and efficacy, coal tar is relevant in low-income settings (Paghdal And Schwartz 2009). Phenobarbital represents another example. In many high-income countries, it has been replaced by newer antiseizure drugs for long-term seizure prevention and is mainly used in specific situations, such as status epilepticus (Pressler et al. 2023; NICE 2025b). However, because of its efficacy, low cost, availability, and long clinical experience, phenobarbital remains important for seizure prevention in many LMICs (Brodie And Kwan 2012; Bankole et al. 2024). Some drugs remain pharmacologically valuable, but for individual EML-listed indications require correction or specification (category C), as seen in metronidazole and sulfadiazine. Metronidazole remains important for anaerobic and protozoal infections, but it is not anymore recommended in the treatment of C. difficile infection (NICE 2021; van Prehn et al. 2021). However, for its first-choice indications, it is widely used and has an acceptable safety and efficacy (Hernández Ceruelos et al. 2019). Sulfadiazine remains relevant in toxoplasmosis, where it is part of recommended combination treatment regimens, but it is not equally supported for broader anti-infective indications such as malaria (RKI 2018; Dunay et al. 2018; CDC 2024c); Castaño et al. 2022; Konstantinovic et al. 2019). Drugs that are considered obsolete (category D) have a low current therapeutic value, compared with treatment alternatives. This includes dextran, which has largely been replaced by safer and equally effective plasma substitutes (Miao And Guthmiller 2025). Although it is effective as a plasma volume expander, its use is limited by serious adverse effects, making it more a historical than a current treatment option (Martin 2019; Baglin 2012). Chloramphenicol represents another example. It remains effective against susceptible pathogens, but is now mainly restricted to reserve use, for example in bacterial meningitis (EMC 2022). Its clinical role is strongly limited by relevant toxicity, including rare but severe haematological adverse effects, and by the availability of safer and more favourable alternatives (Moffa and Brook 2015; Sethi And Sethi 2025; BfR 2014). The categorization by therapeutic value separates two central patterns. On the one hand, many retained drugs are still clearly valuable and remain important because of reproducible efficacy, clinical indispensability, and broad therapeutic use. On the other hand, some retained drugs show limited current value, either because their role has become restricted to niche situations or because their benefit–risk profile is no longer favourable compared with available alternatives. Therefore, the assessment of EML-listed indications does not only support conclusions on appropriate or questionable EML listing, but also allows a broader interpretation of the current therapeutic value of long-retained drugs. Limitations and strengths The analysis has several limitations, mainly related to scope, assessment criteria, and comparability of sources. It focuses on retained drugs listed in both the 1st and 24th editions of the EML and therefore does not provide a full longitudinal assessment of all intermediate EML editions. The pharmacological assessment was based on listed indications, guideline recommendations, evidence of efficacy and safety, scope of clinical usage, and public health need. However, these aspects differ between countries, guidelines, and health-care settings, and the classification into constant, increasing, or declining scope of clinical use and therapeutic value cannot be completely objective. Because of the large number of drugs and aspects included in the analysis, it was not feasible to perform a fully systematic literature search. Although publications representing different healthcare settings and viewpoints were considered where possible, bias in the included references cannot be completely excluded. Excluded aspects of the assessment include dosing, formulations, paediatric use, cost-effectiveness, national EML modifications, and the distinction between core and complementary lists. Furthermore, a conceptual limitation relates to the operationalisation of “therapeutic value” categories. In particular, the distinction between “robust evidence” and “magnitude of benefit” cannot be fully separated within the applied framework, and the categorisation of drugs was primarily based on available evidence certainty, guideline interpretation, and overall benefit–risk considerations. In this context, the assessment of “favourable benefit–risk ratio” should be understood as a pragmatic categorisation rather than a strict binary distinction. A key strength of this analysis is the pharmacologically orientated reassessment of long-standing retained drugs beyond their historical preservation on the EML. Instead of considering retention alone as proof of unchanged therapeutic value, the analysis evaluates the current listed indications, evidence of efficacy and safety, guideline support, and scope of clinical usage. This allows an evaluation of drugs and indications, whether they require discussion for deletion or correction. Furthermore, an algorithm-based, transparent assignment to therapeutic value categories was applied. The analysis highlights both the importance of many long-established drugs and the need for regular reassessment to ensure that retained drugs remain clinically justified, therapeutically relevant, and consistent with the fundamental purpose of the EML: to provide a rational basis for essential pharmacotherapy. Conclusions The present analysis shows that retained drugs can be characterised by distinct patterns (Table 1, 5 and S1, Fig. 2–4). Many drugs retained constant scopes in clinical use and remain part of basic care. Their therapeutic value is therefore not primarily based on novelty, but evidence of pharmacological efficacy and broad scope in clinical use. Some drugs gained relevance through expanded indications, pharmacological versatility, or increasing epidemiological demands. Conversely, several drugs show declining use. However, declining scopes in clinical uses is not equivalent to obsolescence, since some drugs retain relevant niche, reserve, or low-resource value. Therefore, the trend in the scope of clinical use has to be distinguished from the therapeutic value of a drug. 19 retained drugs were identified where a deletion from the EML requires discussion. Main reasons for obsolescence are restricted or second-choice indications, reduced efficacy, pathogen resistance, toxicity, declining availability, or replacement by more favourable alternatives (Table S1). The structured assessment algorithm of therapeutic value (Fig. 4) resulted in four groups of retained drugs: clearly valuable, valuable in niche use, indication correction needed, and low value or obsolete. This distinction is important because long-term retention can indicate true therapeutic value, but can also preserve drugs whose current role is restricted, outdated, or no longer sufficiently justified (Table 5). Contrary to the expectation that retained drugs would exclusively represent universally accepted and indispensable medicines, the analysis demonstrated a heterogeneous spectrum ranging from indispensable to obsolete drugs. Figure 5 visualizes a simplified model which summarizes the central finding of the study that historical retention on the EML should not be interpreted as a direct equivalent of unchanged therapeutic importance. Spectrum of therapeutic relevance among retained drugs. The trapezoid model visualizes that long-term EML retention does not exclusively represent universally accepted and indispensable medicines, but rather an increasing heterogeneous continuum of therapeutic relevance. The horizontal axis represents decreasing therapeutic relevance from left to right. The left side of the spectrum (dark/light green) reflects drugs with high current relevance and strong justification for continued EML inclusion, whereas the right side (yellow/orange) reflects drugs with declining relevance and questionable continued EML listing Future EML revisions should not only evaluate whether a drug remains on the EML, but whether each listed indication is still supported by current evidence, guideline recommendations, risk–benefit ratios, scope of clinical usage, and therapeutic value. Drugs with clearly unfavourable profiles and available superior alternatives should be discussed for deletion. Drugs relevant mainly in niche or low-resource settings should remain listed when justified, but their setting-specific role should be explicitly stated. Beyond clinical and pharmacological considerations, it should also be acknowledged that incentive structures may influence the expansion of listed drugs on the EML. In particular, the development of new drugs or the generation of additional evidence supporting expanded indications is highly supported by academic research and commercial interest. In contrast, there are comparatively limited or less explicit incentives for the systematic reassessment and potential removal of older medicines, even when their relative therapeutic value may have declined. This asymmetry may contribute to a tendency towards expansion of the EML over time. In the future, the EML will require a careful balance between rational drug selection and the inclusion of innovative therapies. This is particularly relevant with the increasing introduction of highly specialized and costly treatments, raising the question of whether such medicines can be considered essential in addition to being rational for a specific condition. Therefore, it is proposed that EML chapters are reviewed on a regular basis rather than primarily through ad hoc recommendations to the Committee. Furthermore, additions and deletions should not be initiated solely through external applications, but the Committee should also proactively identify and address relevant issues, for example through structured consensus-based approaches such as a Delphi process (WHO 2025a; Hasson et al. 2025). Lastly, the decision-making process should be made transparent and clearly explained. While this is generally well addressed in technical reports, the most recent technical report from 2025 lacks comprehensiveness in this regard (WHO 2025a). Such approaches would preserve the global function of the EML while improving its pharmacological precision and ensuring that retained drugs and all other included drugs on the EML remain not only historically important, but clinically and therapeutically justified. Supplementary Information Below is the link to the electronic supplementary material. (DOCX 219 KB) Author contribution L.J.B. and R.S. contributed to the study's conception and design. L.J.B. performed data collection. L.J.B. and R.S. performed data analysis. L.J.B. wrote the first draft of the paper. L.J.B. and R.S. commented on the first draft and read and approved the final manuscript. All authors read and approved the final version. The authors declare that all data were generated in-house and that no paper mill was used. DeepL was used exclusively for language editing and proofreading. Funding Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability All source data for this study are available upon reasonable request from the authors. Declarations Ethics approval This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (https://www.mhh.de/en/research/good-scientific-practice). The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). Consent to publish Not applicable because publicly available information is used as a data source. Competing interests R.S. in the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors (https://link.springer.com/journal/210/submission-guidelines#Instructions%_20for%20Authors_Competing%_20Interests). L.J.B. declares no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials (DOCX 219 KB) Data Availability Statement All source data for this study are available upon reasonable request from the authors.